Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase Two, Superiority Trial

Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD). We tested efficacy of bumetanide on core symptom domains using a mono-center, parallel-group, participant-randomized, double-blind, placebo-controlled phase-2 superiority trial in a tertiary Netherlands hospital.

Source: Journal of the American Academy of Child and Adolescent Psychiatry - July 26, 2020 Category: Psychiatry Authors: Jan J. Sprengers, Dorinde M. van Andel, Nicolaas PA. Zuithoff, Mandy G. Keijzer-Veen, Annelien JA. Schulp, Floortje E. Scheepers, Marc R. Lilien, Bob Oranje, Hilgo Bruining Tags: New Research Source Type: research